Efficacy and Predictors of Response to a Low-FODMAP Diet in Patients With Overlap of Functional Dyspepsia and Irritable Bowel Syndrome: A Prospective Multicentre Randomized Clinical Trial
In brief
Low-FODMAP diet nearly doubles response in patients with overlapping IBS and dyspepsia
In a randomized trial of 112 adults, 59% on a low-FODMAP diet met combined symptom-response criteria after 6 weeks, compared with 32% receiving traditional dietary advice. Symptoms recurred in 91% of initial diet responders after FODMAPs were reintroduced, but the trial was short and predictors of benefit remain exploratory.
- Journal
- Alimentary pharmacology & therapeutics (Q1)
- Published
- 18 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Riya Khurana, Manjeet Kumar Goyal, Gurseen Rakhra, Sanjeev Sachdeva, Vaishali Bharadwaj, Venkatesh Vaithiyam, et al.
- PMID
- 43053466
- DOI
- 10.1111/apt.71100
Why clinicians should know about it
- Picked for Gastroenterology (top studies of the week, 22 November 2026): Randomized dietary treatment trial for functional dyspepsia-IBS overlap
Abstract
BACKGROUND AND AIMS: Functional dyspepsia (FD) frequently coexists with irritable bowel syndrome (IBS), resulting in a complex clinical phenotype characterized by prominent postprandial symptoms and limited treatment options. We compared the efficacy of a low-fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet with traditional dietary advice (TDA) in this population. METHODS: In this multicentre randomized, assessor-blinded trial, adults fulfilling Rome IV criteria for both FD and IBS were assigned to a low-FODMAP diet (LFD) or TDA for 6 weeks, with structured dietitian support. The primary endpoint was a combined response, defined by both a ≥ 50-point reduction in IBS Symptom Severity Scale and a ≥ 30% reduction in Short-Form Nepean Dyspepsia Index (SFNDI) symptom scores at 6 weeks. Among patients who responded to LFD, FODMAPS were systematically reintroduced from 7 to 12 weeks, and patients who had symptom recurrence were defined as 'true responders'. Baseline predictors of true LFD response were evaluated using univariable and multivariable logistic regression (CTRI/2025/04/084483). RESULTS: A total of, 112 participants were randomized (LFD, n = 59; TDA, n = 53; mean age 40.9 ± 15.2 years, 42.8% males). After 6 weeks, the combined IBS-FD response rates were 59.3% versus 32.1% (p = 0.005) in the LFD and TDA arms respectively. After FODMAP reintroduction, 32/35 patients (91.4%) had symptom recurrence (true responders). Improvements in symptom and disease-specific quality-of-life scores favoured LFD. Exploratory multivariable predictors of response to LFD were postprandial distress sub-type and a higher (worse) baseline SF-NDI quality-of-life score. CONCLUSION: A low-FODMAP diet was superior to traditional dietary advice in improving global symptoms and HRQoL in patients with FD-IBS overlap, supporting targeted fermentable carbohydrate restriction as an effective, personalized therapeutic strategy.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.